Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients

• Type: Article in International Scientific Journal
• Date: 2023

Authors

Pinheiro, M (Author) Other; Peixoto, A (Author) Other; Rocha, P (Author) Other; Santos, C (Author) Other; Escudeiro, C (Author) Other; Veiga, I (Author) Other; Porto, M (Author) Other; Guerra, J (Author) Other; Barbosa, A (Author) Other; Pinto, C (Author) Other; Arinto, P (Author) Other; Resende, A (Author) Other; Manuel R Teixeira (Author) ICBAS

Journal

Title: Pharmacogenetics and Genomics

Vol. 33

Pages: 165-171

ISSN: 1744-6872

Publisher: Wolters Kluwer Health

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00Z-0X6

DOI: 10.1097/fpc.0000000000000505

Abstract (EN): Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause severe fluoropyrimidine-related toxicity. We assessed the frequency of the four most common and well-established DPYD variants associated with fluoropyrimidine toxicity and implemented a relatively low-cost and high-throughput genotyping assay for their detection. Methods This study includes 457 patients that were genotyped for the DPYD c.1129-5923C>G, c.1679T>G, c.1905 + 1G>A and c.2846A>T variants, either by Sanger sequencing or kompetitive allele specific PCR (KASP) technology. Of these, 172 patients presented toxicity during treatment with fluoropyrimidines (post-treatment group), and 285 were tested before treatment (pretreatment group). Results Heterozygous DPYD variants were identified in 7.4% of the entire series of 457 patients, being the c.2846A>T the most frequent variant. In the post-treatment group, 15.7% of the patients presented DPYD variants, whereas only 2.5% of the patients in the pretreatment group presented a variant. The KASP assays designed in this study presented 100% genotype concordance with the results obtained by Sanger sequencing. Conclusions The combined assessment of the four DPYD variants in our population increases the identification of patients at high risk for developing fluoropyrimidine toxicity, supporting the upfront routine implementation of DPYD variant genotyping. Furthermore, the KASP genotyping assay described in this study presents a rapid turnaround time and relatively low cost, making upfront DPYD screening feasible in clinical practice.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7